drugset / Trial / NCT00991861

Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis

NCT00991861

Phase 2 Completed 100 enrolled Almirall, S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to determine the efficacy, safety and tolerability of either a once or twice daily topical application of LAS41007 compared to a twice daily application of LAS106521 in the treatment of actinic keratosis.

Timeline

Start
2009-08
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac Other / unclassified Topical
Comparator LAS106521 Unknown Topical

Indications